Velcade Articles
5.6% annual growth forecast for multiple myeloma drug market to 2020
21 December 2011
Hematologist-oncologists view Velcade more favorably than Revlimid or Thalomid for multiple myeloma; report
1 November 2011
UK NICE backing for Celgene and Janssen multiple myeloma drugs, Thalidomide and Velcade; FDA fast-tracks Istodax sNDA
20 June 2011
Draft guidance from UK’s NICE recommends Celgene and Janssen Cilag multiple myeloma drugs; Sanofi-Aventis’ Multaq approved for AF
27 August 2010
Johnson & Johnson’s 4th-qtr/full year 2009 sales and profit exceed expectations, but forecast disappoints
27 January 2010
Johnson & Johnson’s 3rd quarter disappoints, as generics gouge leading drugs, though cost cuts help profits
14 October 2009
J&J 1st qtr hit by market drop; keeps guidance
15 April 2009
Janssen Japan down on end of KHK deal
14 April 2009
Japan stock market week to March 30, 2009
31 March 2009
Zolinza/Velcade combo enters Ph IIb MM trial
26 January 2009
Millennium presents Ph I Velcade trial results
15 December 2008
UK govt adopts two-tier NHS for Rx drugs
10 November 2008
Takeda's recurring profit down 70%
10 November 2008
UK cancer groups turn against Celgene over NICE refusal
10 November 2008
EC approves expanded indication for Velcade
15 September 2008
Millennium publishes results of VISTA trial
8 September 2008
Telik's proteasome blockers show anticancer activity
1 September 2008
UK volume price plan for GSK's Tyverb
11 August 2008
Japan stock market week to June 30, 2008
7 July 2008
Millennium/J&J's FDA approval for Velcade
30 June 2008
New Rx drug pricing models for UK
21 April 2008
Japan stock market week to April 14, 2008
21 April 2008
Millennium accepts $8.8B bid from Takeda
14 April 2008
EMEA restricts use of Millennium/J&J's Velcade
31 March 2008
Stock Commentary - New York week to March 17, 2008
24 March 2008
Millennium expands Velcade program in NHL
25 February 2008
Millennium's 2007 net income beats forecasts
18 February 2008
J&J's 4th-qtr 2007 sales jump 16.6%, EPS up 11%
28 January 2008
Mixed responses to UK Parliamentary c'ttee's report on the NICE; review delays slammed
21 January 2008
Velcade helps exceed Millennium's targets
14 January 2008
UK Parliament c'tee calls for NICE review
14 January 2008
Kosan's pivotal Ph III tanespimycin trial starts recruiting
14 January 2008
Millennium to get $40M milestone from Ortho Biotech
7 January 2008
Stock Commentary - New York week to Dec 10, 2007
17 December 2007
Velcade boosts remission rates in MM
17 December 2007
ImmunoGen's candidates produce "encouraging results"
17 December 2007
Millennium's 3rd-qtr loss down 88%
21 November 2007
Stock Commentary - New York week to Nov 5, 2007
12 November 2007
Belinostat shows promise in range of cancer indications
5 November 2007
J&J's NHS money-back guarantee warning
22 October 2007
EU to investigate UK's drug "postcode lottery"
10 September 2007
Recruitment opens in Ph II Velcade combo MM trial
20 August 2007
UK cancer drug access under fire again
20 August 2007
Millennium initiates Ph III trial of Velcade
23 July 2007
Stock Commentary - New York week to July 2, 2007
9 July 2007
Strong Ph I/II data for Keryx' perifosine
9 July 2007
Velcade produces 54% CR rate in MM
9 July 2007
Combined Velcade plus Doxil gets FDA OK for MM
28 May 2007
Millennium identifies Velcade efficacy biomarkers
23 April 2007
Ph II trial of belinostat and Velcade initiated
2 April 2007
J&J's 4th qtr 2006 EPS beats analysts' estimate
29 January 2007
Ortho Biotech seeks OK for Doxil/Velcade combo
29 January 2007
UK patient moves to Scotland for cancer drug
22 January 2007
Strong preclinical data for EntreMed's Panzem
18 December 2006
PXD101 shows promise in Phase II MM trial
18 December 2006
Millenium/Ortho Biotech to market Velcade in US
6 November 2006
Millennium sees mixed results in 3rd-qtr 2006
6 November 2006
NICE defensive about Velcade decision
30 October 2006
NICE set to confirm negative Velcade stand
30 October 2006
Stock Commentary - New York week to Sept 25, 2006
2 October 2006
Kosan selects names for its lead Hsp90 drugs
28 August 2006
Millennium Pharma gets FDA OK for Velcade sNDA
14 August 2006
UK's NICE rejects cancer drug, ponders Herceptin
7 August 2006
Millennium's 2nd-qtr losses down to $17.7M
7 August 2006
HGS' HGS-ETR1+Velcade enters Ph II MM trial
31 July 2006
Millennium's 1st-qtr 2006 loss narrows 43%
15 May 2006
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
